GEN Exclusives

More »

GEN News Highlights

More »
Apr 11, 2007

Affitech Contracts With ProBioGen for Cancer Antibody Production

  • ProBioGen will develop a biopharmaceutical cell line for high-level production of one of Affitech’s lead oncology candidates.

    Under the terms of the agreement, ProBioGen will apply its cell-generation process for biopharmaceutical cell lines relying on the unique vectors and its pre-optimized CHO starter cell. This will be combined with an automated cloning process to identify and develop a high producer line, which should be particularly suitable for a fed-batch development process.

    “Our unique approach in developing high producer cell lines combined with our royalty-free business model is very attractive to our customers and provides them with one of the crucial key features for a successful production process,” says Michael Schlenk, CEO at ProBioGen.

    Commenting on the agreement, Martin Welschof, CEO of Affitech, remarks, "While several of our in-house discovered human antibodies are in various stages of preclinical development, in order to meet the demands of our ambitious development program for oncology antibody therapeutics, we have chosen a partner who offers us a high degree of flexibility and a compatible service-based development model.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?